Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment
Autore:
Emilien, G; Maloteaux, JM; Ponchon, M;
Indirizzi:
Catholic Univ Louvain, Pharmacol Lab, B-1200 Brussels, Belgium Catholic Univ Louvain Brussels Belgium B-1200 , B-1200 Brussels, Belgium Catholic Univ Louvain, Diabet & Nutr Unit, B-1200 Brussels, Belgium Catholic Univ Louvain Brussels Belgium B-1200 , B-1200 Brussels, Belgium
Titolo Testata:
PHARMACOLOGY & THERAPEUTICS
fascicolo: 1, volume: 81, anno: 1999,
pagine: 37 - 51
SICI:
0163-7258(199901)81:1<37:PMODRP>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUCAGON RECEPTOR GENE; ACTING INSULIN ANALOG; ALPHA-GLUCOSIDASE INHIBITION; HYPOGLYCEMIC AGENT CS-045; GLYCOGEN-SYNTHASE GENE; COMBINATION THERAPY; SUBCUTANEOUS INJECTION; SULFONYLUREA RECEPTOR; NONDIABETIC SUBJECTS; ANTIDIABETIC AGENTS;
Keywords:
insulin; diabetes; antihyperglycaemics; thiazolinediones; amylin; sulphonylureas; troglitazone;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
134
Recensione:
Indirizzi per estratti:
Indirizzo: Emilien, G 127 Rue Henri Prou, F-78340 Les Clayes Bois, France 127 Rue Henri Prou Les Clayes Bois France F-78340 ois, France
Citazione:
G. Emilien et al., "Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment", PHARM THERA, 81(1), 1999, pp. 37-51

Abstract

Glycaemic control in Type I diabetes has been proven efficient in preventing microvascular and neurological complications. The assumption that good control of hyperglycaemia may also have significant impact on alleviation ofcomplications in Type 2 diabetes has gained growing support in recent years. Measures such as body weight reduction and exercise improve the metabolic defects, but pharmacological therapy is most frequently used. The sulphonylureas stimulate insulin secretion. Metformin and troglitazone increase glucose disposal and decrease hepatic glucose output without causing hypoglycaemia. Acarbose helps to spread the dietary carbohydrate challenge to endogenous insulin over time. These pharmacological treatments can improve bloodglucose regulation in Type 2 diabetes patients. However, the key to strictglycaemic control with use of exogenous insulin lies in the creation of delivery methods that emulate physiologic insulin secretion. Insulin lispro, a recombinant insulin analogue, is identical to human insulin except for the transposition of proline and lysine at positions 28 and 29 in the C-terminus of the B chain. Evidence suggests that patients perceive their quality of life to be improved with insulin lispro when compared with regular humaninsulin, and that satisfaction with treatment is greater with the insulin analogue. Numerous new pharmacological approaches are under active investigation, with the aim of promoting insulin secretion, improving the action ofinsulin, or slowing carbohydrate absorption. With respect to continuous subcutaneous insulin infusion therapy and implantable pumps, despite that this approach is not widely utilised, it appears to bring us as close to achieving glycaemic control as is feasible with current treatment approaches, However, general application of such technology requires significant improvements in several areas, such as improvement of patency of catheter, pump failures due to early battery depletion incidents, and pump miniaturisation. Future perspective resides on insulin analogues with longer half-lives that would provide better basal insulin coverage in association with fast-actinganalogues. PHARMACOL. THER. 81(1):31-51, 1999. (C) 1998 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:32:13